Guy MacDonald
Chairman at SCYNEXIS, INC.
Net worth: 32 340 $ as of 30/04/2024
Guy MacDonald active positions
Companies | Position | Start | End |
---|---|---|---|
SCYNEXIS, INC. | Chairman | 04/06/2015 | - |
Director/Board Member | 27/11/2014 | 04/06/2015 | |
Independent Dir/Board Member | 27/11/2014 | - |
Career history of Guy MacDonald
Former positions of Guy MacDonald
Companies | Position | Start | End |
---|---|---|---|
TETRAPHASE PHARMACEUTICALS, INC. | Director/Board Member | 01/01/2008 | 01/08/2019 |
Chief Executive Officer | 01/01/2008 | 01/08/2019 | |
President | 01/01/2008 | 01/08/2019 | |
SPRING BANK PHARMACEUTICALS, INC. | Director/Board Member | - | 09/10/2014 |
Chairman | - | 17/08/2015 | |
IDENIX PHARMACEUTICALS INC | Chief Operating Officer | 01/08/2003 | 01/01/2008 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2003 | 01/01/2003 |
Training of Guy MacDonald
University Of Dundee | Undergraduate Degree |
Statistics
International
United States | 6 |
United Kingdom | 2 |
Operational
Director/Board Member | 3 |
Chairman | 2 |
Chief Operating Officer | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
SCYNEXIS, INC. | Health Technology |
Private companies | 3 |
---|---|
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
F-Star Therapeutics, Inc. (United States)
F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
- Stock Market
- Insiders
- Guy MacDonald
- Experience